NCT02137785已完成3 期
A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 269
- 试验地点
- 13
- 主要终点
- Complete Clearance Rate
研究概览
简要总结
The purpose of this study is to determine if Levulan Photodynamic Therapy (PDT) is safe and effective in the treatment of actinic keratoses on the upper arms and hands
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Four to fifteen Grade 1/2 actinic keratosis lesions (AKs) on one upper extremity
排除标准
- •Pregnancy
- •grade 3 and/or atypical >1cm AKs within Treatment Area
- •history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or photodermatosis
- •lesions suspicious for skin cancer (skin cancer not ruled out by biopsy) or untreated skin cancers within the Treatment Area
- •skin pathology or condition which could interfere with the evaluation of the test product or requires the use of interfering topical or systemic therapy
- •Subject is immunosuppressed
- •unsuccessful outcome from previous ALA-PDT therapy
- •currently enrolled in an investigational drug or device study
- •has received an investigational drug or been treated with an investigational device within 30 days prior to the initiation of treatment
- •known sensitivity to one or more of the vehicle components (ethyl alcohol, isopropyl alcohol, laureth 4, polyethylene glycol)
- •use of the following topical preparations on the extremity to be treated:
- •Keratolytics including urea (greater than 5%), alpha hydroxyacids [e.g.glycolic acid, lactic acid, etc. greater than 5%], salicylic acid (greater than 2%) within 2 days of initiation of treatment.
- •Cryotherapy within 2 weeks of initiation of treatment
- •Retinoids, including tazarotene, adapalene, tretinoin, within 4 weeks of initiation of treatment.
- •Microdermabrasion, laser ablative treatments, ALA-PDT, chemical peels, 5-FU, diclofenac, ingenol mebutate, imiquimod or other topical treatments for AK within 8 weeks of initiation of treatment.
- •use of systemic retinoid therapy within 6 months of initiation of treatment.
研究组 & 干预措施
ALA
Experimental
干预措施: Aminolevulinic Acid (ALA) (Drug)
ALA
Experimental
干预措施: Blue Light Photodynamic Therapy Illuminator (BLU-U) (Device)
Vehicle
Placebo Comparator
干预措施: Topical Solution Vehicle (Drug)
Vehicle
Placebo Comparator
干预措施: Blue Light Photodynamic Therapy Illuminator (BLU-U) (Device)
结局指标
主要结局
Complete Clearance Rate
时间窗: Week 12
proportion of subjects in each treatment group with a count of zero lesions in the Treatment Area
次要结局
- Complete Clearance Rate(Week 8)
- AK Clearance Rate(Baseline and Week 8)
- Subject Satisfaction Score(Week 12)
研究者
研究点 (13)
Loading locations...
相似试验
已完成
2 期
Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)Actinic KeratosisNCT01475955DUSA Pharmaceuticals, Inc.235
已完成
2 期
Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)Keratosis, ActinicNCT01458587DUSA Pharmaceuticals, Inc.70
已完成
4 期
Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic CheilitisActinic CheilitisNCT02409732Dartmouth-Hitchcock Medical Center24
已完成
2 期
Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic TherapyActinic KeratosisNCT02239679DUSA Pharmaceuticals, Inc.166
已完成
1 期
Phase 1/2 Sequentially Staged Safety Study in Healthy Subjects and Subjects With Mild AcneAcneNCT01490736Dermira, Inc.129